Skip to main content
Erschienen in: Cancer Microenvironment 1-3/2017

19.05.2017 | Original Article

Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women

verfasst von: Ritu Lakhtakia, Adil Aljarrah, Muhammad Furrukh, Shyam S. Ganguly

Erschienen in: Cancer Microenvironment | Ausgabe 1-3/2017

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer (BC) in Oman affects younger women and has a more aggressive course. Clinical and biological variables like age, pregnancy, tumor size, type, grade, receptor expression and proliferation predict disease aggression but there is no direct predictor of metastasis except lymphovascular invasion. Epithelial-mesenchymal transition (EMT) is characterized by epithelial cells losing epithelial and acquiring mesenchymal morpho-immunophenotypic characteristics. In tumors, EMT-like transitions may signify a metastatic phenotype and have features in common with cancer stem cells (CSC) which show resistance to chemotherapy. This study aimed to identify EMT and CSC phenotypes in metastatic and non-metastatic breast cancer in Omani women and their association with conventional clinico-pathological predictors of BC. In a retrospective study of ninety-six Omani women with breast cancer, the association of age, pregnancy/lactation, tumor size, type, grade, ductal carcinoma insitu (DCIS), lymphovascular invasion, hormone/ HER2 receptor expression and Ki67 proliferation index (Ki67 PI) was tested with EMT/ CSC phenotype and metastasis. Young age ≤ 40 years, lymphovascular invasion and EMT had a strong association with metastasis; CSC approached significance. Vimentin expression in tumor cells, fibronectin and MMP-11 in stroma were reliable markers of EMT; dual EMT and CSC phenotype (Vim+/ CD44+/ CD 24−/low) had a strong association with apocrine variant, basal-like tumors and triple negative cancers. EMT had a strong association with Ki67 proliferation index (PI) and CSC with HER2-like tumors and distant metastasis. These select markers may be useful in metastasis-prediction in pre-treatment biopsies.
Literatur
2.
Zurück zum Zitat Witz IP. The tumor microenvironment: the making of a paradigm. Tumor Microenvironment 2(1):S9-S17 Witz IP. The tumor microenvironment: the making of a paradigm. Tumor Microenvironment 2(1):S9-S17
3.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890CrossRefPubMed
4.
Zurück zum Zitat Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 7(21):10123–10128CrossRef Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 7(21):10123–10128CrossRef
5.
Zurück zum Zitat Orimo A, Gupta PB, Sgroi DC, Seisdedos A, Delauney T, Naem R et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 21(3):335–348CrossRef Orimo A, Gupta PB, Sgroi DC, Seisdedos A, Delauney T, Naem R et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 21(3):335–348CrossRef
6.
Zurück zum Zitat Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 4(6):818–829CrossRef Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 4(6):818–829CrossRef
7.
8.
Zurück zum Zitat Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329CrossRefPubMed Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329CrossRefPubMed
10.
Zurück zum Zitat Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed
11.
Zurück zum Zitat Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 3(1):7–15CrossRef Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 3(1):7–15CrossRef
12.
Zurück zum Zitat Mani SA, Guo W, Liao MJ, Eaton EN, Ayannan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMedPubMedCentral Mani SA, Guo W, Liao MJ, Eaton EN, Ayannan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820–5828CrossRefPubMedPubMedCentral Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820–5828CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67(5):1979–1987CrossRefPubMed Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67(5):1979–1987CrossRefPubMed
15.
Zurück zum Zitat Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD (2011) A systems view of epithelial–mesenchymal transition signaling states. Clin Exp Metastasis 28:137–155CrossRefPubMed Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD (2011) A systems view of epithelial–mesenchymal transition signaling states. Clin Exp Metastasis 28:137–155CrossRefPubMed
16.
Zurück zum Zitat Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784–2789CrossRefPubMedPubMedCentral Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784–2789CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194–207CrossRefPubMed Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194–207CrossRefPubMed
18.
Zurück zum Zitat Tomaskovik-Crook E, Thompsom EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213CrossRef Tomaskovik-Crook E, Thompsom EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213CrossRef
19.
Zurück zum Zitat Kimbung S, Kovaks A, Bendahl P-A, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I (2013) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. doi:10.1016/j.molonc.2013.10.002 Kimbung S, Kovaks A, Bendahl P-A, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I (2013) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. doi:10.​1016/​j.​molonc.​2013.​10.​002
20.
Zurück zum Zitat Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106(33):13820–13825CrossRefPubMedPubMedCentral Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106(33):13820–13825CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumor infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713. doi:10.1038/bjc.2013.634 Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumor infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705–2713. doi:10.​1038/​bjc.​2013.​634
22.
23.
Zurück zum Zitat Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100(3):248–251. doi:10.1002/jso.21268 CrossRefPubMed Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100(3):248–251. doi:10.​1002/​jso.​21268 CrossRefPubMed
25.
Zurück zum Zitat Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual. Springer-Verlag, New York Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual. Springer-Verlag, New York
26.
Zurück zum Zitat Lakhani S (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon Lakhani S (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon
27.
Zurück zum Zitat Elston CW, Ellis I O (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 19; 403-410. Author Commentary Histopathology 2002; 41(3A):151–2 Elston CW, Ellis I O (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 19; 403-410. Author Commentary Histopathology 2002; 41(3A):151–2
28.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
29.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed
30.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Glentis A, Gurchenkov V, Matic Vignjevic D (2014) Assembly, heterogeneity, and breaching of the basement membranes. Cell Adhes Migr 8(3):236–245CrossRef Glentis A, Gurchenkov V, Matic Vignjevic D (2014) Assembly, heterogeneity, and breaching of the basement membranes. Cell Adhes Migr 8(3):236–245CrossRef
32.
Zurück zum Zitat Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S et al (2001) Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology 60(3):274–281CrossRefPubMed Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S et al (2001) Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology 60(3):274–281CrossRefPubMed
33.
Zurück zum Zitat Harisi R, Kenessey I, Olah JN, Timar F, Babo I, Pogany G et al (2009) Differential inhibition of single and cluster type tumor cell migration. Anticancer Res 29(8):2981–2985PubMed Harisi R, Kenessey I, Olah JN, Timar F, Babo I, Pogany G et al (2009) Differential inhibition of single and cluster type tumor cell migration. Anticancer Res 29(8):2981–2985PubMed
39.
Zurück zum Zitat Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558CrossRefPubMed Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558CrossRefPubMed
40.
Zurück zum Zitat Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H (2005) Transcriptional activation of integrin beta6 during the epithelial mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339–347CrossRefPubMedPubMedCentral Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H (2005) Transcriptional activation of integrin beta6 during the epithelial mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339–347CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Raymond WA, Leong AS (1989) Vimentin--a new prognostic parameter in breast carcinoma? J Pathol 158:107–114CrossRefPubMed Raymond WA, Leong AS (1989) Vimentin--a new prognostic parameter in breast carcinoma? J Pathol 158:107–114CrossRefPubMed
42.
43.
Zurück zum Zitat Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRefPubMed Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRefPubMed
44.
45.
Zurück zum Zitat Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704CrossRefPubMed Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704CrossRefPubMed
46.
Zurück zum Zitat Christensen L (1992) The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 26:1–39PubMed Christensen L (1992) The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 26:1–39PubMed
47.
Zurück zum Zitat Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP (2008) Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 32:345–353CrossRefPubMed Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP (2008) Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol 32:345–353CrossRefPubMed
48.
Zurück zum Zitat Barrallo-Gimeno A, Nieto MA (2005) The snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161CrossRefPubMed Barrallo-Gimeno A, Nieto MA (2005) The snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161CrossRefPubMed
49.
Zurück zum Zitat Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T et al (2007) Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925–930CrossRefPubMed Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T et al (2007) Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925–930CrossRefPubMed
50.
Zurück zum Zitat Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601CrossRefPubMed Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601CrossRefPubMed
52.
Zurück zum Zitat Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159PubMed Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159PubMed
53.
Zurück zum Zitat Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32:650–658CrossRefPubMed Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32:650–658CrossRefPubMed
56.
Zurück zum Zitat Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76CrossRefPubMedPubMedCentral Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185:191–203CrossRefPubMed Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185:191–203CrossRefPubMed
58.
Zurück zum Zitat Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988CrossRefPubMedPubMedCentral Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679CrossRefPubMed Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679CrossRefPubMed
61.
Zurück zum Zitat Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M (2011) Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomark Prev 20(9):1865–1872CrossRef Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M (2011) Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomark Prev 20(9):1865–1872CrossRef
62.
Zurück zum Zitat Sung CO, Park CK, Kim SH (2011) Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol 24:1060–1068CrossRefPubMed Sung CO, Park CK, Kim SH (2011) Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol 24:1060–1068CrossRefPubMed
63.
Zurück zum Zitat Ryu HS, Park DJ, Kim HH, Kim WH, Lee HS (2012) Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 43:520–528CrossRefPubMed Ryu HS, Park DJ, Kim HH, Kim WH, Lee HS (2012) Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 43:520–528CrossRefPubMed
65.
Zurück zum Zitat Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z (2015) Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res Treat 154(1):45–55CrossRefPubMed Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z (2015) Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res Treat 154(1):45–55CrossRefPubMed
66.
Zurück zum Zitat Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. J Pathol 136(1):219–227 Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. J Pathol 136(1):219–227
67.
Zurück zum Zitat Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603CrossRefPubMedPubMedCentral Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7:464–473CrossRefPubMed Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7:464–473CrossRefPubMed
71.
Zurück zum Zitat Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A et al (2017) HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol 39(3):1010428317695028. doi:10.1177/1010428317695028 CrossRefPubMed Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A et al (2017) HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol 39(3):1010428317695028. doi:10.​1177/​1010428317695028​ CrossRefPubMed
Metadaten
Titel
Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women
verfasst von
Ritu Lakhtakia
Adil Aljarrah
Muhammad Furrukh
Shyam S. Ganguly
Publikationsdatum
19.05.2017
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1-3/2017
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-017-0194-9

Weitere Artikel der Ausgabe 1-3/2017

Cancer Microenvironment 1-3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.